InvestWiser

Enzymatica publ AB

ENZYNasdaq StockholmHealthcareMarket value 583 m SEK
2.40SEK +1.3%
last day · Price as of 18 November 2026

The answer first

Does Enzymatica beat the market?

Yes, Enzymatica has beaten the market over the last year.

Enzymatica+27.0%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 48% of Nordic stocks

    • Quality72
    • Value5
    • Trend77

    No. 63 of 195 in healthcare

Max for seven days

Follow Enzymatica with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Enzymatica

From today, at a price of 2.40 SEK. Write why you follow Enzymatica, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Enzymatica

Your first answer is free, no account needed.

Do you own Enzymatica, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Enzymatica and a few more. Free, no card.

Past year against the exchange and Super Stock
Enzymatica+27.0%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Enzymatica has risen 27.0% over the past year, including dividends.
  • Overall, Enzymatica ranks better than 48% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 85.4%. The price is 92.6% below its peak now.

What do analysts think of Enzymatica?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

48

Quality, value and trend together. Better than 48% of Nordic stocks.

No. 63 of 195 in healthcare

Quality72
The company · Fundamentals: the accounts

High A solid company: it earns well on its money and has healthy finances.

No. 81 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.18
  • Asset turnoverSales divided by everything the company owns0.42
  • Return on equityProfit divided by equity−44.2%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value5
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 166 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity6.1
  • P/SPrice divided by sales11.2
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend77
The share price · Technical: the price trend

High Tailwind in the share price: it has risen more than most over the last year.

No. 46 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months+29.0%
  • 6 months+0.8%
  • 9 months+20.0%
  • 12 months+27.0%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
+23.4%
3 years, per year
−10.7%
5 years, per year
−25.0%
10 years, per year
−4.4%
Largest fall, 3 years
−85.4%
From a peak to the bottom
From the peak now
−92.6%
How far the price is from the peak
Volatility, 1 year
69.1%
How much the price swings over a year
Beta, 1 year
0.19
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Enzymatica

One fund we follow owns Enzymatica. The share is how much of the fund the stock makes up.

  • Sweden1

From the funds' latest known holdings.

About Enzymatica

Enzymatica publ AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 17 employees.

Enzymatica AB (publ), a life science company, develops and sells medical devices for infectious diseases. The company's product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care under Penzyme technology. The company was incorporated in 2007 and is headquartered in Lund, Sweden.

See the full analysis of Enzymatica.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market